ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
Newswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of…
Read more ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis